Fluzone
MELAS Syndrome
Stanford UniversityPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the MELAS Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sonlicromanol Khondrion BV | Phase 3 | BB |
Idebenone Michio Hirano | Phase 2 | B |
ARG The Hospital for Sick Children | Phase 2 | B |
Zagociguat Tisento Therapeutics | Phase 2 | CCC |
Tti-0102 Thiogenesis Therapeutics, Inc. | Phase 2 | CCC |
View all 10 →
Same molecule, other indications
Fluzone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →